Compounded GLP-1 Ban 2026: What’s Legal Now and What’s Next

Is There a Compounded GLP-1 Ban in 2026?

Not a total one. No law or final FDA rule bans every compounded GLP-1, but the legal room to make them has shrunk to patient-specific prescriptions.

Large-scale copies of Wegovy, Ozempic, Zepbound and Mounjaro were legal only while those drugs sat on the FDA’s shortage list. That ended in 2025. What remains is 503A compounding: a licensed pharmacy making a product for one named patient, with a documented medical reason it must differ from the approved drug.

The FDA’s April 30, 2026 proposal would also stop 503B outsourcing facilities from making these drugs from raw ingredient. Headlines call this the compounded GLP-1 ban. It’s still a proposal, but every FDA move since 2024 has pointed the same way.

Compounded semaglutide and tirzepatide are not FDA-approved, and the agency doesn’t review them for safety, effectiveness or quality before sale.

What Has the FDA Done So Far? The 2024–2026 Timeline

Since October 2024, the FDA has narrowed compounding step by step. The shortages ended first, then the grace periods, then came marketing crackdowns and the 503B proposal.

We checked each date against FDA pages, the Federal Register or court records on September 26, 2026.

What the Warning Letters Targeted

The letters cite website marketing. None of the letters named here reports testing a product. Each says the company made false or misleading claims, so its drugs were “misbranded.” The same problems repeat:

• SkinnyRx, Strut Health and Eden showed their own names on pictured vials, which implies they made the drugs. They didn’t.
• Strut was cited for “Generic Zepbound, Mounjaro,” and SkinnyRx for “same active ingredient” claims.
• Eden claimed “FDA-licensed 503(a) outsourcing facilities.” The FDA says it doesn’t license or approve any pharmacy.

Our reviews of SkinnyRx, Strut Health and Eden note each letter. On March 9, 2026, Hims & Hers said it would stop advertising compounded GLP-1s. It added that existing patients could switch to FDA-approved drugs when their providers find it appropriate.

When Will the Compounded GLP-1 Ban Be Final?

Nobody outside the FDA knows. As of September 26, 2026, the agency hasn’t published a final decision or a target date, and no law sets a deadline.

The Federal Register notice ran on May 1, 2026 (Docket FDA-2018-N-3240). Comments were due June 30. After a request for 60 more days, the agency granted 30, saying it wanted to avoid “significant delay of Agency action.” Comments closed July 30. Regulations.gov logged 4,279 of them as of August 23.

On paper, the FDA published a notice rather than a rule. The last step is a second notice with its “final determination,” and the agency plans to answer a related Novo Nordisk petition in it.

The FDA found no “clinical need” for outsourcing facilities to make these drugs from bulk while approved versions exist. Lower cost and easier use don’t count, the notice says. “When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need,” FDA Commissioner Marty Makary said on April 30.

What Is the Difference Between 503A and 503B Pharmacies?

A 503A pharmacy compounds for one patient at a time with a prescription. A 503B outsourcing facility makes larger batches under FDA oversight. The April 2026 proposal hits 503B, not 503A.

Here’s how the federal rules compare as of September 2026.

Since mid-2025, 503B facilities haven’t been allowed to make these drugs from bulk ingredient. If a seller says its semaglutide comes from a 503B facility today, ask how.

Is Compounded Semaglutide or Tirzepatide Still Legal Right Now?

Yes, in narrow cases. A 503A pharmacy may compound either drug for a named patient if the product isn’t “essentially a copy” of an approved drug. A documented, significant difference for that patient also qualifies.

The FDA’s copy test is simple. A compounded drug is a copy if it has the same active ingredient, a similar strength and the same route as a drug on the market. A weekly semaglutide shot at Wegovy strengths is one example. The agency restated these rules on April 1, 2026.

There’s one volume allowance. The FDA says it doesn’t intend to act against a pharmacy that fills four or fewer prescriptions of a copy in a calendar month. It frames that as its approach “at this time,” and it doesn’t cover high-volume telehealth orders.

Nothing in the April update says what a prescriber’s documentation must include. Law firm Orrick wrote on May 1, 2026 that “patient preference and cost savings alone are insufficient justifications.”

Does Adding B12 Make Compounded Semaglutide Legal?

Not by itself. In April 2026, the FDA said a semaglutide-plus-B12 injection can still be “essentially a copy.” That applies when both amounts are within 10% of approved products’ strengths. The same test covers other drug combinations.

In June 2026, the FDA also cited Altru Telehealth for saying its B12 blend contained “the FDA approved active ingredient semaglutide.”

Where Are the Gray Zones?

• Custom and “micro” doses: the FDA noted that approved pens come in low strengths and prescribers can slow the step-up. It rejected “patients need lower doses” as a reason for 503B bulk compounding. At a 503A pharmacy, your prescriber’s documented reason decides.
• Pills, drops and lozenges: no compounded oral GLP-1 is FDA-approved. The Wegovy pill is approved oral semaglutide, so a similar compounded pill can count as a copy.
• Salt forms: the FDA knows of no lawful basis for compounding semaglutide sodium or acetate. Ask which form your pharmacy uses.
• Retatrutide and cagrilintide: federal law bars both from compounding.
• State rules: states license 503A pharmacies, and their rules differ. In September 2026, at least three provider sites said they don’t ship compounded GLP-1s to Alabama, Louisiana or Mississippi.

Is Compounded Semaglutide Safe? What FDA Reports Show

Not in the way an approved drug is. Compounded versions never went through the FDA review that Wegovy and Zepbound passed, and the agency keeps logging problems.

As of May 31, 2026, the FDA had 990 adverse-event reports tied to compounded semaglutide. It had more than 730 tied to compounded tirzepatide, per its compounded GLP-1 safety page. A report doesn’t prove the drug caused the problem. The true count is likely higher, because 503A pharmacies don’t have to report.

Dosing mistakes are the clearest risk. In a July 2024 alert, the FDA said most error reports involved patients drawing too much from multi-dose vials. They took 5 to 20 times the intended dose. Some clinicians made 5- to 10-fold errors converting milligrams to “units,” and some patients needed hospital care.

The FDA’s vial advice: throw a vial away 28 days after first use, even if the label says it lasts longer. Use a new needle and syringe for every dose, and don’t use a GLP-1 that arrives warm. On August 12, 2026, the FDA wrote to state medical boards about vial labeling and dosing risks.

Are “Research Peptides” a Safe Backup?

No. Sites selling semaglutide, tirzepatide or retatrutide “for research purposes” or “not for human consumption” are selling unapproved drugs, and the FDA has warned such sellers.

According to the FDA, these products reach consumers with dosing instructions and are “of unknown quality.” You get no prescriber and no licensed pharmacy, and the vial may not hold what the label says. Retatrutide isn’t approved for any use. If your compounded supply ends, these sites are not a safe or legal substitute.

What Should You Do If Your Pharmacy or Provider Stops Supplying You?

Plan your next step with a prescriber before your last dose, so you don’t end up with a gap in treatment.

1. Don’t change your dose to stretch your supply. Ask your prescriber first.
2. Ask your provider three questions. Which pharmacy fills my prescription, and is it 503A or 503B? Will you keep offering this drug? Which FDA-approved drugs can you prescribe?
3. Keep your records. Save your vial label (it shows mg per mL), your dose in mg and the date of your last injection.
4. Check your refund terms. In September 2026, Eden’s terms promised a prorated refund if a treatment becomes unavailable. SkinnyRx said bundles are non-refundable.
5. Price your backups. Check your insurance formulary, the Medicare Bridge rules and the prices below.
6. If you need a new prescriber, find one who offers FDA-approved drugs. See how to get a GLP-1 prescription online and the 7 questions to ask a provider.
7. Don’t stockpile. FDA guidance is to throw away opened vials after 28 days.

What Are Your Options If Compounded GLP-1s Go Away?

Every legal backup is an FDA-approved drug from a prescriber. What changes is how you pay for it. The table shows published prices as of September 2026.

The Bridge runs from July 1, 2026 to December 31, 2027, per CMS. It covers Wegovy (pen or pill), Foundayo and the Zepbound KwikPen, but not Zepbound vials. If you have type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease, ask your plan instead.

Cash prices come from LillyDirect and NovoCare. Neither cash program takes Medicare or other government insurance.

What Happens If the Compounded GLP-1 Ban Is Finalized, or Slips?

Either way, broad compounding doesn’t come back on its own. What differs is how firmly the door closes for 503B facilities.

If the FDA Finalizes It

• Outsourcing facilities couldn’t make semaglutide, tirzepatide or liraglutide from bulk unless a drug returns to the shortage list.
• 503A rules would stay as they are today, with the copy limits above.
• The FDA plans to answer Novo Nordisk’s petition in the same notice.
• More providers may add FDA-approved options and move patients over, as Hims & Hers announced in March 2026. Ask yours what it plans.

If It Slips

• Nothing reopens. Both drugs are already off the bulks list and the shortage list. The Alliance for Pharmacy Compounding put it plainly: “At present, this proposal does not change the status quo.”
• Pressure continues. Orrick noted in May 2026 that Novo Nordisk and Eli Lilly are suing compounders and telehealth firms, and that several state pharmacy boards are investigating.
• A new FDA shortage listing is the one thing that would reopen broad compounding. In court, the compounders’ trade group lost both appeals on August 27, 2026.

How Do You Switch From Compounded to Wegovy or Zepbound Safely?

Switch with your prescriber, follow the brand’s label schedule and never convert doses yourself.

• Brand labels start low and step up in 4-week stages. Wegovy pens run from 0.25 mg to 2.4 mg, plus a 7.2 mg HD pen. Zepbound runs from 2.5 mg to 15 mg. Your prescriber decides where you start.
• Your compounded dose may not match a brand dose one-to-one. Compounded vials come in different strengths, so “units” mean little without the mg per mL. Bring your label.
• Ask when to take your last compounded dose before your first brand dose. Don’t overlap them unless your prescriber tells you to.
• Going from semaglutide to tirzepatide, or back, is a bigger change. It means a new drug with its own label.
• Tell your prescriber if nausea or vomiting gets worse after the switch.

This page is general information, not medical or legal advice. Your prescriber decides your drug and dose.